Trial Profile
Phase II Study of Fulvestrant in Combination With Abemaciclib in Hormone Receptor Positive Adenocarcinoma of Endometrium
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Fulvestrant (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 19 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2026.
- 03 Jul 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2026.